Peter Young

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

A review of market performance and trends in 2018 and first quarter of 2019 for the life sciences industry.

What the new rules mean for Chinese-related investments and acquisitions in the US.